Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 08, 2012 07:00 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Reports Second Quarter and Six Month 2012 Financial Results

NEW HAVEN, Conn., Aug. 8, 2012 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported financial results for the three and six months ended June 30, 2012 and provided an...
August 07, 2012 16:05 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Announces Positive SVR4 Results From Phase 2 Study of Sovaprevir (Formerly ACH-1625) and Advancement of ACH-3102

Sovaprevir (formerly ACH-1625) achieves SVR4 of 85-100% of genotype 1 treatment naive patients treated with sovaprevir for 12 weeks followed by an additional 12 weeks of pegylated-interferon and...
July 31, 2012 16:05 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion to Report Second Quarter 2012 Financial Results and Host Conference Call on August 8, 2012

NEW HAVEN, Conn., July 31, 2012 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that it plans to release second quarter and six-month 2012 financial results on...
July 10, 2012 07:00 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion to Present at the 2012 JMP Securities Healthcare Conference

NEW HAVEN, Conn., July 10, 2012 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging...
June 14, 2012 07:00 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion to Present at 2012 Wells Fargo Securities Healthcare Conference

NEW HAVEN, Conn., June 14, 2012 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging...
June 11, 2012 16:03 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Appoints Kurt Graves to Its Board of Directors

NEW HAVEN, Conn., June 11, 2012 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced the appointment of Kurt Graves to its board of directors as an independent director....
June 06, 2012 16:03 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Announces Resignation of Chief Medical Officer

NEW HAVEN, Conn., June 6, 2012 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced the resignation of Elizabeth A. Olek, D.O., Senior Vice President of Clinical...
May 21, 2012 07:00 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Announces Additional Proof-of-Concept Data With ACH-2684 for the Treatment of Hepatitis C

NEW HAVEN, Conn., May 21, 2012 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported proof-of-concept data from a Phase 1b clinical trial demonstrating that patients with...
May 18, 2012 07:00 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Announces Executive Promotion

NEW HAVEN, Conn., May 18, 2012 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging...
May 15, 2012 07:00 ET | Source: Achillion Pharmaceuticals, Inc.

ACH-3102 Receives Fast Track Designation From the FDA for the Treatment of Chronic Hepatitis C

NEW HAVEN, Conn., May 15, 2012 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today the receipt of a Fast Track designation from the U.S. Food and Drug Administration...